华西证券
Search documents
业绩突破!中小券商锚定2026,新打法曝光!
券商中国· 2026-02-04 05:16
随着2026年时间轴逐步展开,多家中小型券商陆续召开经营工作会议。证券时报记者注意到,不少券商在 2025年取得业绩突破,为"十五五"开局奠定了良好基础。 面对"十五五"开局之年,各家券商正积极谋划未来五年的差异化布局。根据证券时报记者梳理,区域深耕、集 团主业协同、从"通道中介"向"综合服务商"转型、科技赋能等成为2026年券商战略部署的主线,部分中小券商 着力构建与地方经济、股东产业紧密结合的特色化发展路径。 一些已于去年完成股东变更的券商表示,2026年将开启高质量发展新征程;另一些仍受股东问题困扰的券商则 坦言,2026年或将面临多重挑战,但亦需迎难而上。 券业释放好成绩信号 过去一年,伴随着市场行情向好、交投活跃,证券行业业绩整体实现高增长,多家券商也透露了"好成绩"信 息。 东方财富Choice数据显示,截至2月2日,共有17家上市券商披露2025年业绩预告,其中16家预增,另外1家扭 亏为盈。同时,还有5家券商发布了2025年业绩快报,同样皆为报喜。 比如,国泰海通预计归母净利润为275.33亿至280.06亿元,申万宏源预计归母净利润为91亿至101亿元,中金公 司预计归母净利润为85.42亿 ...
超20家上市券商2025年业绩预喜,6家券商归母净利润预计同比增长超100%
Jin Rong Jie· 2026-02-04 03:20
根据Choice数据,截至2026年2月3日,A股和港股市场已有24家上市券商披露业绩预告或业绩快报,且 全部实现净利润正增长。 | 公司简称 | 预告净利润中值 | 预告类型 | 预告净利润变动中值 | 预告净利润 | 预告净利润 | | --- | --- | --- | --- | --- | --- | | | /业绩快报净利润(亿元) | | /业绩快报变动幅度(%) | 上限(亿元) | 下限(亿元) | | 中信证券 | 300.51 | 预增 | 38.46 | | | | 国泰海通 | 277.70 | 预增 | 113.00 | 280.06 | 275.33 | | 招商证券 | 123.00 | 预增 | 18.43 | 1 | i | | 甲万宏源 | 96.00 | 预增 | 84.24 | 101.00 | 91.00 | | 中美公司 | 95.39 | 预增 | 67.50 | 105.35 | 85.42 | | 东方证券 | 56.20 | 预增 | 67.80 | 56.20 | 56.20 | | 方正证券 | 39.70 | 预增 | 80.00 | 40.80 | ...
2025年上市券商业绩稳健增长
Jin Rong Shi Bao· 2026-02-04 02:27
Core Viewpoint - The performance of listed securities firms in the A-share market has shown steady growth, driven by a favorable equity market and increased trading activity, with all reported firms expecting profit increases for 2025 [1][6]. Group 1: Performance of Major Securities Firms - Three securities firms are expected to exceed 10 billion yuan in revenue for 2025: CITIC Securities, China Merchants Securities, and Everbright Securities [2]. - CITIC Securities reported a revenue of 74.83 billion yuan for 2025, a year-on-year increase of 28.75%, and a net profit attributable to shareholders of 30.05 billion yuan, up 38.46% [2]. - China Merchants Securities achieved a total revenue of 24.9 billion yuan and a net profit of 12.3 billion yuan for 2025, both showing growth [3]. - Everbright Securities reported a revenue of 10.863 billion yuan, a 13.18% increase, and a net profit of 3.729 billion yuan, up 21.92% [3]. - Guotai Junan is expected to achieve a net profit of 27.53 billion to 28.01 billion yuan, reflecting a year-on-year growth of 111% to 115% [3]. Group 2: Performance of Small and Medium-sized Securities Firms - Smaller securities firms are demonstrating significant growth resilience through differentiated development based on niche markets and regional advantages [4]. - Huaxi Securities anticipates a net profit of 1.27 billion to 1.65 billion yuan for 2025, representing a year-on-year increase of 74.46% to 126.66% [4]. - Xiangcai Securities expects a substantial net profit growth of 266.4% to 403.8% due to significant increases in wealth management and proprietary business [4]. - Guolian Minsheng is projected to achieve a net profit of 2.008 billion yuan, reflecting a growth of approximately 406% [4]. Group 3: Market Trends and Future Outlook - The overall market activity in 2025 is expected to significantly benefit securities firms, with a total trading volume in the Shanghai and Shenzhen markets reaching 413.78 trillion yuan, marking a historical high [7]. - The average daily trading volume has set a new record, and the margin trading balance reached 2.54 trillion yuan, a 36% year-on-year increase, indicating a recovery in investor confidence [7]. - Analysts remain optimistic about the securities sector's future performance, with expectations of continued growth driven by favorable policies and market conditions in 2026 [7].
泓德基金管理有限公司 关于旗下基金投资关联方承销期内承销证券的公告
Zhong Guo Zheng Quan Bao - Zhong Zheng Wang· 2026-02-03 22:33
登录新浪财经APP 搜索【信披】查看更多考评等级 根据《公开募集证券投资基金运作管理办法》《公开募集证券投资基金信息披露管理办法》及相关法律 法规、各基金基金合同及招募说明书等规定,在履行规定审批程序并经基金托管人同意后,泓德基金管 理有限公司(以下简称"本公司")旗下管理的部分公募基金参与了中电科蓝天科技股份有限公司(以下 简称"电科蓝天")首次公开发行人民币普通股(A股)网下申购。电科蓝天本次发行的承销商国泰海通 证券股份有限公司为本公司部分公募基金托管人或托管人的关联方。电科蓝天发行价格为人民币9.47 元/股,由发行人和承销商根据初步询价结果,综合考虑发行人基本面、市场情况、同行业上市公司估 值水平、有效募集资金需求及承销风险等因素后协商确定。 根据法律法规、基金合同及电科蓝天于2026年2月3日发布的《中电科蓝天科技股份有限公司首次公开发 行股票并在科创板上市网下初步配售结果及网上中签结果公告》,现将本公司涉及上述关联关系的公募 基金获配信息公告如下: ■ 特此公告。 泓德基金管理有限公司 二〇二六年二月四日 泓德悦享一年持有期混合型证券 投资基金开放日常赎回、转换转出业务的公告 公告送出日期:20 ...
8000亿元!央行,最新预告!
券商中国· 2026-02-03 14:45
中国人民银行(下称"央行")2月3日发布公告称,将在2月4日以固定数量、利率招标、多重价位中标方式开展8000亿元买断式逆回购操作,期限为3个月(91天)。 鉴于本月有7000亿元买断式逆回购到期,央行本次操作后将实现净投放1000亿元。 对于本次买断式逆回购加量续作,市场机构普遍认为央行此举主要是为避免政府债券供给带来的流动性冲击。此外,临近春节假期的取现高峰,以及春节假期后税 期叠加资金跨月等因素,都可能扰动2月银行体系流动性。 "2月资金面面临的主要扰动可能是春节及政府债发行节奏。"国金证券固定收益首席分析师尹睿哲在研报中指出,若按照1月发行规模测算,2月政府债净融资规模或 小幅上升2000亿元,且2月春节放假有效工作日可能偏少,发行节奏可能相对集中。 2月有累计1.2万亿元的买断式逆回购到期规模,考虑到月内还有一次6个月期品种操作,且两个期限品种的买断式逆回购已连续8个月净投放,市场机构仍看好两个 期限品种的买断式逆回购实现净投放。 "2月流动性是否出现波澜,最终取决于央行的投放。"华西证券首席经济学家刘郁在研报中预计,2月买断式回购净投放规模或在5000亿元左右,以满足银行的中期 资金需求。对于春节 ...
央行将开展8000亿元买断式逆回购操作!
证券时报· 2026-02-03 12:13
央行大动作。 中国人民银行(下称"央行")2月3日发布公告称,将在4日以固定数量、利率招标、多重价位中标方式 开展8000亿元买断式逆回购操作,期限为3个月(91天)。鉴于本月有7000亿元买断式逆回购到期,央 行本次操作后将实现净投放1000亿元。 证券时报各平台所有原创内容,未经书面授权,任何单位及个人不得转载。我社保留追 究相关 行 为主体 法律责任的权利。 转载与合作可联系证券时报小助理,微信ID:SecuritiesTimes 对于本次买断式逆回购加量续作,市场机构普遍认为央行此举主要是为避免政府债券供给带来的流动性 冲击。此外,临近春节假期的取现高峰,以及春节假期后税期叠加资金跨月等因素,都可能扰动2月银 行体系流动性。 "2月资金面面临的主要扰动可能是春节及政府债发行节奏。"国金证券固定收益首席分析师尹睿哲在研 报中指出,若按照1月发行规模测算,2月政府债净融资规模或小幅上升2000亿元,且2月由于春节放假 有效工作日可能偏少,发行节奏可能相对集中。 2月有累计1.2万亿元的买断式逆回购到期规模,考虑到月内还有一次6个月期品种操作,且两个期限品 种的买断式逆回购已连续8个月净投放,市场机构仍看好 ...
定点爆破
Datayes· 2026-02-03 11:07
Group 1 - The article discusses potential tax adjustments targeting the financial and internet service sectors, with concerns that the tax rate for internet value-added services may rise from 6% to align more closely with the 32% rate of the liquor industry due to high profit margins [1][2] - There are rumors that high-tech enterprises may no longer qualify for the 15% preferential tax rate, shifting to a standard 25% corporate income tax rate, which could significantly impact major internet companies like Tencent and Alibaba [1][2] - The recent VAT law changes have raised investor concerns about possible tax increases across various sectors, including internet services and finance [2] Group 2 - Citigroup believes the likelihood of widespread tax increases in the short term is low, but the era of significant tax reductions may be over, as fiscal pressures mount due to factors like declining land transfer revenues and increased social security expenditures [6] - The article notes that the current economic environment shows weak domestic demand, which may limit the government's ability to implement broad tax hikes [6] Group 3 - The A-share market experienced a rebound, with the Shanghai Composite Index rising by 1.29%, and trading volume decreased by 411.38 billion yuan compared to the previous day [12] - The aerospace sector saw significant activity, with several stocks hitting the daily limit, driven by upcoming space missions and increased interest in space-related technologies [12][13] - The article highlights the performance of various sectors, noting that the power equipment, defense, and machinery sectors saw the largest net inflows of capital, while non-ferrous metals and banking sectors faced outflows [30][38] Group 4 - The article mentions that the central government's recent policy document emphasizes agricultural modernization and the integration of AI and technology in agriculture, which could create investment opportunities in related sectors [19] - In the semiconductor industry, major Chinese manufacturers are planning significant expansions to close the gap with market leaders amid a global chip shortage [20] Group 5 - The CDN industry is expected to experience growth as cloud service providers have begun raising prices, breaking a long-standing trend of price declines [21] - The robotics sector is seeing increased investment, with significant funding rounds reported for companies focused on humanoid robots and AI applications [22]
华西证券(002926) - 华西证券股份有限公司2026年面向专业投资者公开发行公司债券(第二期)在深圳证券交易所上市的公告
2026-02-03 09:12
华西证券股份有限公司 2026 年面向专业投资者公开发行公司债 券(第二期)在深圳证券交易所上市的公告 根据深圳证券交易所债券上市的有关规定,华西证券股份有限公司 2026 年 面向专业投资者公开发行公司债券(第二期)符合深圳证券交易所债券上市条件, 将于 2026 年 2 月 4 日起在深圳证券交易所上市,并面向专业投资者中的机构投 资者交易,交易方式包括匹配成交、点击成交、询价成交、竞买成交和协商成交。 债券相关要素如下: 华西证券股份有限公司 年 月 日 | 债券名称 | 华西证券股份有限公司 2026 年面向专业投资者公开发 | | --- | --- | | | 行公司债券(第二期) | | 债券简称 | 华股 26 02 | | 债券代码 | 524644 | | 信用评级 | 主体 AAA/债项 AAA | | 评级机构 | 联合资信评估股份有限公司 | | 发行总额(亿元) | 20.00 | | 债券期限 | 454 天 | | 票面年利率(%) | 1.77 | | 利率形式 | 固定利率 | | 付息频率 | 每年付息一次 | | 发行日 | 年 月 日至 年 月 日 2026 1 28 ...
黄金巨震下的积存金:有人连续补仓12次,银行纷纷出手防风险
经济观察报· 2026-02-03 03:51
"补仓!补仓!还是补仓!"近日,京东金融平台博主"黄金蛋炒饭"的"金友圈"被这几个字刷屏。 屏幕上刺目的绿色数字(亏损)成了这一轮黄金暴跌中,高位 入场个人投资者的写照。随着黄金市场震荡风险增加,有的银 行发布风险提示,有的银行早已悄然提高黄金积存金的准入门 槛。 作者:刘颖 封图:图虫创意 2026年2月2日下午,伦敦现货黄金价格跌破4500美元/盎司,国内积存金价格同步下探,他在京 东金融平台上果断以1016.27元/克买入近200克黄金积存金。这已是自今年1月29日金价创新高 以来,他的第12次补仓。 1月29日早盘,伦敦现货黄金价格冲破5500美元/盎司历史峰值,国内黄金积存金市场瞬间沸腾, 投资者入市热情高涨。然而,狂欢仅持续不到24小时。当日深夜,伦敦现货黄金价格半小时内暴 跌逾7%,突如其来的跳水让市场猝不及防。 但在京东金融"金友圈"里,不少投资者并未恐慌,反而将此次下跌视作难得的"上车机会",博 主"黄金蛋炒饭"便是其中之一。1月29日23时,他果断出手,分别以1225.27元/克、1195.06 元/克、1160元/克的价格购入黄金积存金共计超250克,开启了本轮黄金震荡行情中的补仓之 路 ...
华西证券:小核酸药物凭借技术突破性与治疗差异化 成为精准医疗核心赛道
Zhi Tong Cai Jing· 2026-02-03 02:01
Group 1 - The small nucleic acid drug industry is recommended to focus on three categories: clinical progress type (key targets with Phase III data + beneficiaries of medical insurance), technology platform type (extracellular delivery + multi-target technology companies), and international cooperation type (local companies endorsed by MNCs) to capture dual dividends from new drug launches and data readout windows [1] - Small nucleic acid drugs have become a core track in precision medicine due to their technological breakthroughs and therapeutic differentiation, covering thousands of rare and chronic disease-related targets [1] - The global market for small nucleic acid drugs is expected to grow from $2.7 billion in 2019 to $5.7 billion in 2024, with a CAGR of 16.2%, and projected to reach $20.6 billion by 2029, driven by the increase in chronic diseases and significant drug commercialization [2] Group 2 - The industry is entering a high growth phase, with over 50% of the 19 drugs currently on the market targeting rare diseases, while the proportion of chronic diseases is expected to gradually increase [2] - Key players in the industry include Alnylam and Ionis, which dominate the market with their technological barriers, while local companies like Reebio and Bowang Pharmaceutical are focusing on niche areas [2] - 2025 is anticipated to be a pivotal year for small nucleic acid drugs, with several key drugs expected to achieve significant sales milestones and clinical endpoints [3]